Protagonist Therapeutics (PTGX) Competitors

Protagonist Therapeutics (NASDAQ:PTGX) and Ascendis Pharma A/S (NASDAQ:ASND) are both mid-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their risk, dividends, valuation, analyst recommendations, media sentiment, community ranking, earnings, profitability and institutional ownership.

Does the media refer more to PTGX or ASND?

In the previous week, Ascendis Pharma A/S had 6 more articles in the media than Protagonist Therapeutics. MarketBeat recorded 11 mentions for Ascendis Pharma A/S and 5 mentions for Protagonist Therapeutics. Protagonist Therapeutics' average media sentiment score of 1.08 beat Ascendis Pharma A/S's score of 0.64 indicating that Protagonist Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Protagonist Therapeutics	2 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Ascendis Pharma A/S	2 Very Positive mention(s)	3 Positive mention(s)	3 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

Is PTGX or ASND more profitable?

Protagonist Therapeutics has a net margin of 52.76% compared to Ascendis Pharma A/S's net margin of -130.33%. Protagonist Therapeutics' return on equity of 34.68% beat Ascendis Pharma A/S's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Protagonist Therapeutics	52.76%	34.68%	30.98%
Ascendis Pharma A/S	-130.33%	N/A	-48.77%

Which has more risk and volatility, PTGX or ASND?

Protagonist Therapeutics has a beta of 2.23, suggesting that its stock price is 123% more volatile than the S&P 500. Comparatively, Ascendis Pharma A/S has a beta of 0.65, suggesting that its stock price is 35% less volatile than the S&P 500.

Do insiders and institutionals have more ownership in PTGX or ASND?

98.6% of Protagonist Therapeutics shares are owned by institutional investors. 5.4% of Protagonist Therapeutics shares are owned by insiders. Comparatively, 40.0% of Ascendis Pharma A/S shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Which has stronger earnings and valuation, PTGX or ASND?

Protagonist Therapeutics has higher earnings, but lower revenue than Ascendis Pharma A/S. Ascendis Pharma A/S is trading at a lower price-to-earnings ratio than Protagonist Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Protagonist Therapeutics	$60M	36.44	-$78.96M	$2.66	13.79
Ascendis Pharma A/S	$288.08M	27.61	-$521.07M	-$8.08	-16.22

Does the MarketBeat Community favor PTGX or ASND?

Ascendis Pharma A/S received 162 more outperform votes than Protagonist Therapeutics when rated by MarketBeat users. Likewise, 66.57% of users gave Ascendis Pharma A/S an outperform vote while only 60.83% of users gave Protagonist Therapeutics an outperform vote.

Company	Underperform	Outperform
Protagonist Therapeutics	Outperform Votes 278 60.83%	Underperform Votes 179 39.17%
Ascendis Pharma A/S	Outperform Votes 440 66.57%	Underperform Votes 221 33.43%

Do analysts prefer PTGX or ASND?

Protagonist Therapeutics presently has a consensus target price of $53.78, indicating a potential upside of 46.61%. Ascendis Pharma A/S has a consensus target price of $192.07, indicating a potential upside of 46.54%. Given Protagonist Therapeutics' stronger consensus rating and higher possible upside, equities research analysts plainly believe Protagonist Therapeutics is more favorable than Ascendis Pharma A/S.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Protagonist Therapeutics	0 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	3.00
Ascendis Pharma A/S	0 Sell rating(s)	1 Hold rating(s)	13 Buy rating(s)	0 Strong Buy rating(s)	2.93

Summary

Protagonist Therapeutics beats Ascendis Pharma A/S on 13 of the 19 factors compared between the two stocks.